TCF7L2

Across TCGA pan-cancer cohorts, TCF7L2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TCF7L2 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher TCF7L2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TCF7L2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where TCF7L2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.658	0.326	.005	23	view →
LUAD	DFS	Median	II,III,IV	0.277	0.697	.005	15	view →
HNSC	OS	Median	IV	0.858	0.501	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TCF7L2–PDAC (DFS)

Open the PDAC breakdown →